Ostatné · BLCO
Bausch + Lomb Corporation
Fundamenty firmy Healthcare · Medical Instruments & Supplies · Canada
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 13 hodnotení
nákup
- Najnižší cieľ
- 16,00
- Priemerný cieľ
- 19,04
- Najvyšší cieľ
- 24,00
- Potenciál
- +11,3 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 0,22 | 0,20–0,26 | 0,18 | +20,5 % |
| budúci štvrťrok | 0,35 | 0,32–0,39 | 0,32 | +10,3 % |
| tento rok | 0,81 | 0,73–0,86 | 0,51 | +58,5 % |
| budúci rok | 1,11 | 0,99–1,30 | 0,81 | +37,2 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 1,4 mld. | 1,3 mld. | +7,0 % |
| budúci štvrťrok | 1,5 mld. | 1,4 mld. | +5,9 % |
| tento rok | 5,5 mld. | 5,1 mld. | +7,7 % |
| budúci rok | 5,8 mld. | 5,5 mld. | +5,9 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 8 365 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 9 056 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 79 830 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 109 275 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 25 147 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 186 163 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 3 354 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 50 325 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 39 332 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 11 749 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 37 089 | 10.08. |
| Munsch (Frederick John)Senior Officer of Issuer | iná transakcia | 77 397 | 10.08. |
Kto vlastní akcie
Slávni investori: Howard Marks · 1.1 % Carl Icahn · 0.7 % Dan Loeb · 0.0 % · nový
Icahn Carl C0,98 %
Deutsche Bank AG0,96 %
Oaktree Capital Management LP0,96 %
Shaw D.E. & Co., Inc.0,93 %
Davidson Kempner Capital Management LP0,88 %
Goldentree Asset Management LP0,74 %
Price (T.Rowe) Associates Inc0,60 %
CASPIAN CAPITAL, LP0,56 %
O firme (popis z Yahoo Finance, anglicky)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Technické signály
- Rastový trend – Kurz nad SMA50 aj SMA200, SMA50 nad SMA200
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou BLCO.